Keywords: Insufficient Sleep, Sleep Duration, All-Cause Mortality, Cardiometabolic Risk, Insulin Resistance, Type 2 Diabetes Prevention, Longevity, Preventive Medicine, Dose-Response Meta-Analysis, Sleep Biomarkers
Introduction
Sleep has long occupied a marginal position in preventive medicine, treated as a lifestyle preference rather than a biological necessity on par with nutrition and physical activity. This framing is increasingly difficult to sustain. Longitudinal cohort data accumulated over the past two decades consistently show that adults who habitually sleep fewer than seven hours per night face a measurably higher risk of death from any cause, and that this excess risk is mediated in substantial part through cardiometabolic disease, the very disease category that longevity and wellness programs are designed to prevent [1-5].
For an industry built on extending healthy lifespan and preventing metabolic disease, sleep duration represents an unusually tractable target: it is inexpensively measurable, modifiable through behavioral and digital interventions, and mechanistically linked to the glucose, lipid, and inflammatory pathways that already anchor most longevity risk models. Yet sleep remains underused as a clinical or programmatic variable relative to diet and exercise. This review synthesizes the epidemiological and mechanistic evidence connecting insufficient sleep to reduced life expectancy, and considers what that evidence implies for AI-enabled longevity and metabolic-disease prevention programs.
The Scale of the Problem: Sleep Deficiency in Modern Populations
Insufficient sleep is common rather than exceptional. According to the 2024 National Health Interview Survey, 30.5% of U.S. adults slept less than seven hours per night on average, with the highest prevalence which is 34.5% among adults aged 50 to 64, the age band in which cardiometabolic and longevity interventions are most heavily concentrated. This falls well short of the threshold recommended by the American Academy of Sleep Medicine and Sleep Research Society, whose joint consensus statement advises a minimum of seven hours of sleep per night for adults to support optimal health [1,2].
The gap between recommended and actual sleep duration is therefore not a marginal phenomenon confined to shift workers or clinical insomnia populations. It is a population-level exposure affecting roughly one in three adults, which is precisely the scale at which it becomes relevant to public health and, by extension, to any technology platform attempting to model or reduce population-level mortality and metabolic disease risk.
Sleep Duration and All-Cause Mortality: The Epidemiological Evidence
The association between short sleep and all-cause mortality has been established across multiple independent meta-analyses spanning different decades and populations. Cappuccio and colleagues pooled data from 16 prospective studies comprising 27 cohort samples, more than 1.38 million participants, and 112,566 deaths, and found that short sleep duration was associated with a 12% increase in the relative risk of death (RR 1.12, 95% CI 1.06–1.18) [3].
Subsequent dose-response analyses have refined this picture into a U-shaped curve rather than a simple linear relationship. Yin and colleagues, in a systematic review and dose-response meta-analysis of prospective cohort studies, reported that relative risk of all-cause mortality rose by 6% per hour of sleep below seven hours and by 13% per hour of sleep above seven hours, with the lowest risk consistently observed at approximately seven hours per night; the same analysis found comparable dose-response relationships for cardiovascular disease, coronary heart disease, and stroke [4].
The most comprehensive synthesis to date, published in 2025, pooled 79 cohort studies and confirmed this U-shaped pattern with even greater precision: short sleep (<7 hours) carried a 14% higher mortality risk (HR 1.14, 95% CI 1.10–1.18) and long sleep (≥9 hours) carried a 34% higher mortality risk (HR 1.34, 95% CI 1.26–1.42) relative to 7–8 hours, with the excess risk associated with long sleep duration more pronounced in women. Taken together, these three analyses, spanning more than 1.4 million participants across 15 years of publication, converge on the same conclusion: sleep duration is an independent, quantifiable, and modifiable predictor of premature death, with an effect size comparable in magnitude to several established behavioral risk factors already embedded in longevity risk models [5].
Biological Pathways Linking Sleep Loss to Reduced Lifespan
Metabolic Dysregulation and Diabetes Risk
Mechanistic studies help explain why the mortality association is plausible rather than merely statistical. In controlled laboratory studies, healthy young adults subjected to recurrent partial sleep restriction developed measurable decreases in glucose tolerance and insulin sensitivity within days, alongside neuroendocrine shifts, reduced leptin and elevated ghrelin that increased subjective hunger and appetite. Spiegel and colleagues concluded that chronic voluntary sleep curtailment, now endemic in industrialized populations, constitutes a novel and independent risk factor for weight gain, insulin resistance, and type 2 diabetes, placing sleep alongside diet composition and physical inactivity as a direct driver of metabolic disease [6].
Cardiovascular Risk and Systemic Inflammation
The same dose-response meta-analysis that quantified mortality risk also found parallel associations between sleep duration and incident cardiovascular disease, coronary heart disease, and stroke, consistent with a shared causal pathway. Short sleep is thought to elevate cardiometabolic risk through sustained activation of the sympathetic nervous system and hypothalamic-pituitary-adrenal axis, resulting in elevated blood pressure, low-grade systemic inflammation, and arterial stiffening over time. These pathways overlap substantially with the mechanisms nutrition and exercise interventions are designed to modify, which is one reason sleep is difficult to treat as a separable risk factor in practice [4].
Toward Biomarkers of Sleep-Related Cardiometabolic Risk
A growing research effort is now attempting to move beyond self-reported sleep duration toward objective, biology-based signatures of sleep debt. Depner’s 2023 review describes early progress using omics-based technologies to identify biochemical biomarkers that link habitual short sleep to cardiometabolic risk, derived primarily from experimental sleep-restriction studies. Such biomarkers, once validated in free-living populations, could identify which individuals with short sleep are at greatest metabolic risk and which are most likely to benefit from sleep-focused intervention, a precision-medicine framing that aligns directly with the risk-stratification approach used across longevity and metabolic-disease prevention platforms [7].
Implications for Longevity Medicine and Precision Prevention
For organizations building AI-driven longevity and metabolic-disease prevention tools, three implications follow directly from this evidence base. First, sleep duration and sleep regularity warrant inclusion as a core input variable in mortality and metabolic risk models, not as a secondary wellness metric; the effect sizes reported above are large enough to materially shift individual risk estimates. Second, wearable- and app-derived sleep data create an opportunity to detect chronic short or long sleep patterns passively and at scale, well before downstream glucose or cardiovascular abnormalities become clinically apparent. Third, as biomarker research matures, combining objective sleep metrics with metabolic biomarkers such as fasting glucose, HbA1c, and inflammatory markers may allow more precise identification of individuals for whom a sleep-focused intervention is likely to yield the greatest reduction in long-term mortality risk.
Clinical and Public Health Recommendations
Given that roughly one-third of adults fall short of the recommended seven-hour minimum, closing this gap should be treated as a population-level prevention priority rather than an individual lifestyle choice alone. Practical priorities include routine screening for sleep duration and sleep disorders (particularly insomnia and obstructive sleep apnea) within metabolic disease and longevity clinics; integration of validated sleep tracking into existing digital health platforms; and targeted outreach to demographic groups shown to carry the highest burden of short sleep, including adults aged 50 to 64. Public health messaging should also make explicit that both insufficient and excessive sleep carry elevated mortality risk, since a purely “more is better” framing is not supported by the dose-response evidence [1,2,4,5].
Conclusion
The evidence linking insufficient sleep to decreased life expectancy is no longer preliminary. Multiple large-scale meta-analyses spanning over a million participants demonstrate a consistent, dose-dependent relationship between short sleep duration and all-cause mortality, substantially mediated by impaired glucose metabolism, insulin resistance, and cardiovascular strain. For a field focused on extending healthy lifespan and preventing metabolic disease, sleep deserves to be treated as a primary, modifiable pillar of prevention, measured and managed with the same rigor currently applied to diet and exercise. Embedding sleep duration and quality into risk models and intervention design is a comparatively low-cost, high-yield opportunity to move the needle on both metabolic disease incidence and long-term mortality risk [3-7].
Reference
1. Ng AE, Black LI, Adjaye-Gbewonyo D. Short sleep duration and sleep difficulties among adults: United States, 2024. NCHS Data Brief. 2026 Apr;(559):1-12.
2. Watson NF, Badr MS, Belenky G, Bliwise DL, Buxton OM, Buysse D, et al. Joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society on the recommended amount of sleep for a healthy adult: methodology and discussion. Sleep. 2015;38(8):1161-1183.
3. Cappuccio FP, D’Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep. 2010;33(5):585-592.
4. Yin J, Jin X, Shan Z, Li Y, Shen H, Xu M, et al. Relationship of sleep duration with all-cause mortality and cardiovascular events: a systematic review and dose-response meta-analysis of prospective cohort studies. J Am Heart Assoc. 2017;6(9):e005947.
5. Győrffy B. Imbalanced sleep increases mortality risk by 14-34%: a meta-analysis. GeroScience. 2025;47(3):4545-4566.
6. Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep loss: a novel risk factor for insulin resistance and type 2 diabetes. J Appl Physiol (1985). 2005;99(5):2008-2019.
7. Depner CM. Biomarkers linking habitual short sleep duration with risk of cardiometabolic disease: current progress and future directions. Front Sleep. 2023;2:1293941.